SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma informs about company updates

16 Mar 2020 Evaluate

Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Bliss GVS Pharma has informed that the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq.ft. and is intended to further augment the production capacities for the Company. ‘The company has a robust pipeline of formulations ready at its R&D unit for WHO Pre qualification along with US and EU Markets for Tech-Transfer & Scale Up for this unit and foresee a healthy business growth from its new Unit. In line with commitment towards sustainability, a significant portion of the energy requirement of this facility will be met by captive solar power generation units’ said Gagan Harsh Sharma, Vl-Strategy & Business Development, of the company. The Company has received necessary permissions for the facility from the relevant authorities to commence tech-transfer/ validation activities.

The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma Share Price

253.40 -4.95 (-1.92%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×